Furuhashi M

References (1)

Title : Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy - Furuhashi_2020_Cardiovasc.Diabetol_19_89

Author(s) : Furuhashi M , Sakuma I , Morimoto T , Higashiura Y , Sakai A , Matsumoto M , Sakuma M , Shimabukuro M , Nomiyama T , Arasaki O , Node K , Ueda S

Ref : Cardiovasc Diabetol , 19 :89 , 2020

Abstract :

PubMedSearch : Furuhashi_2020_Cardiovasc.Diabetol_19_89

PubMedID: 32539832

Furuhashi M

References (1)

1. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy - Furuhashi_2020_Cardiovasc.Diabetol_19_89